ILF3 (4G2) Monoclonal Antibody

$Lane 1: Rat Heart; Lane 2: 293 Cells; Probed with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:1000, overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: Rat Heart; Lane 2: 293 Cells; Probed with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:1000, overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100 in A431 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100 in A431 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100 in SH-SY5Y cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100 in SH-SY5Y cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100 in SiHa cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100 in SiHa cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human Tonsil tissue incubated with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Tonsil tissue incubated with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Colon tissue incubated with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Colon tissue incubated with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Prostate tissue incubated with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Prostate tissue incubated with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse Testis tissue incubated with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse Testis tissue incubated with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse Kidney tissue incubated with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse Kidney tissue incubated with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Flow cytometric analysis of K562 cells with ILF3 (4G2) Monoclonal Antibody (bsm-54383R) at a 1:100 dilution (purple) compared with an unlabeled control (cells without incubation with primary antibody; yellow).

Applications

WB
FCM
IHC-P
IF(IHC-P)
IF(ICC)

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bsm-54383R
Product Name	ILF3 (4G2) Monoclonal Antibody
Applications	WB, FCM, IHC-P, IF(IHC-P), IF(ICC)
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Recombinant protein of N-terminal human ILF3.
Clonality	Monoclonal
Clone #	4G2
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition	Store at 4C for up to 2 weeks. For long term storage, store at -20C in small aliquots to prevent freeze-thaw cycles.
Target
Gene ID	3609
Swiss Prot	Q12906
Subcellular location	Nucleus
Synonyms	Interleukin enhancer-binding factor 3; Double-stranded RNA-binding protein 76; M-phase phosphoprotein 4; Nuclear factor associated with dsRNA; Nuclear factor of activated T-cells 90 kDa; Translational control protein 80; DRBP76; MPP4; NFAR; NF-AT-90; TCP80; ILF3
Background	RNA-binding protein that plays an essential role in the biogenesis of circular RNAs (circRNAs) which are produced by back-splicing circularization of pre-mRNAs. Within the nucleus, promotes circRNAs processing by stabilizing the regulatory elements residing in the flanking introns of the circularized exons. Plays thereby a role in the back-splicing of a subset of circRNAs. As a consequence, participates in a wide range of transcriptional and post-transcriptional processes. Binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs. Upon viral infection, ILF3 accumulates in the cytoplasm and participates in the innate antiviral response. Mechanistically, ILF3 becomes phosphorylated and activated by the double-stranded RNA-activated protein kinase/PKR which releases ILF3 from cellular mature circRNAs. In turn, unbound ILF3 molecules are able to interact with and thus inhibit viral mRNA
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(IHC-P)	1:50-200
IF(ICC)	1:50-200